Lv2
146 积分 2025-12-05 加入
Ligation of Intersphincteric Fistula Tract Versus Mucosal Advancement Flap in Patients With High Transsphincteric Fistula-in-Ano
20天前
已完结
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
21天前
已完结
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
21天前
已完结
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
21天前
已完结
In active Crohn disease, risankizumab increased clinical remission and endoscopic response at 12 wk
21天前
已关闭
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials
21天前
已完结
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
21天前
已完结
Effects of fluvoxamine on morphine-induced inhibition of gastrointestinal transit, antinociception and hyperlocomotion in mice
2个月前
已完结
The global burden of inflammatory bowel disease: from 2025 to 2045
3个月前
已完结
Microbiota in inflammatory bowel disease: mechanisms of disease and therapeutic opportunities
3个月前
已完结
皖公网安备34019202002308
